Main menu

NEW YORK (GenomeWeb) – Roka Biosciences announced after the close of the market Thursday that its fourth quarter revenues rose nearly 27 percent year over year.

For the three-month period ended Dec. 31, Roka's revenues climbed to $1.9 million from $1.5 million the year before. Roka said that it had 53 of its Atlas molecular diagnostic systems placed with customers under commercial agreements as of the end of 2016, compared with 41 at the end of 2015.